Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the pharma industry. This time, you get to discover 5 hand-picked startups tackling ovarian cancer.
Global Startup Heat Map highlights 5 Top Startups tackling Ovarian Cancer out of 140
The insights of this data-driven analysis are derived from the Big Data & Artificial Intelligence-powered StartUs Insights Discovery Platform, covering 2.093.000+ startups & scaleups globally. The platform gives you an exhaustive overview of emerging technologies & relevant startups within a specific field in just a few clicks.
The Global Startup Heat Map below reveals the distribution of the 140 exemplary startups & scaleups we analyzed for this research. Further, it highlights 5 pharma startups that we hand-picked based on criteria such as founding year, location, funding raised, and more. You get to explore the solutions of these 5 startups & scaleups in this report. For insights on the other 135 ovarian cancer solutions, get in touch.
Click to download
Tradewind Bioscience works on Antibody Therapeutics
Antibody therapeutics target specific antigens on cancer cells to elicit an immunogenic response. Pharma startups and companies alike are working on different monoclonal antibodies targeting cancers such as ovarian cancer but also renal cancer and colorectal cancer. However, challenges such as tumor cells developing resistance to therapy remain. This is why pharma startups are continuously innovating to improve therapies and expand their use.
US-based startup Tradewind Bioscience develops antibody therapeutics for ovarian cancer. The startup is targeting secreted proteins that play a role in tumorigenesis. Tradewind Bioscience develops monovalent and bispecific antibodies that attack cancer cells and inhibit blood vessel formation in tumors. The startup’s lead drug candidate is currently undergoing in vivo antibody validation.
Adcendo advances Antibody-Drug Conjugates (ADCs)
Off-target toxicity of cancer drugs often leads to adverse side effects such as hair loss, gastrointestinal (GI) perforation, and skin problems. Antibody-drug conjugates combine the specificity of antibodies and the cytotoxicity of the drug payload. This results in the delivery of the drug with high specificity to the cancer cells. This way, ADCs maximize the efficacy of cancer treatment while minimizing side effects.
Adcendo is a Danish startup that develops novel targets for antibody-drug conjugates. The startup is targeting a particular collagen receptor present in many types. It leverages the cargo-carrying capacity of this receptor to deliver the drug inside cancer cells. The startup’s pipeline includes treatments for different cancer indications including, ovarian cancer, soft tissue sarcoma, glioblastoma, leukemia, etc.
Enara Bio offers Cancer Immunotherapies
Ovarian cancer is generally detected in advanced stages when surgeries and chemotherapy have poor survival rates. Immunotherapies use patients’ own immune systems to tackle cancer cells and show promise in the treatment of many cancers. Encouraged by this development, pharma startups are working on cancer immunotherapies for the treatment of advanced ovarian cancer.
British startup Enara Bio offers targeted cancer immunotherapies. The startup’s EDAPT platform investigates genomic dark matter to develop Dark Antigens on the surfaces of cancer cells. It then identifies T-cell receptors that elicit potent anti-tumor responses against these antigens. Currently, the startup is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
Bioeclipse Therapeutics provides Immuno-Oncology Therapeutics
Immunotherapies target cancer cells by identifying particular proteins on their cell surface. However, tumors generally evolve mechanisms to evade this. This lowers the efficacy of cancer treatment, as well as leads to disease recurrence and drug resistance. This is why pharma startups are developing immuno-oncology-based combination therapeutics to treat cancers.
US-based startup Bioeclipse Therapeutics uses its proprietary platform to develop immuno-oncology therapeutics. CRX100, the startup’s lead candidate, combines the locating ability of cytokine-induced killer (CIK) cells and the killing ability of oncolytic viruses. By attacking the tumor in multiple ways, it ensures that tumors do not evade treatment. CRX100 is undergoing clinical investigation for the treatment of epithelial ovarian cancer, gastric cancer, osteosarcoma, and others.
BioVaxys develops a Tumor Cell Vaccine
Therapeutic tumor cell vaccines find applications in the treatment of different cancers such as ovarian cancer, prostate cancer, and melanoma. Such vaccines administer irradiated tumor cells or their lysates to elicit an immune response. By presenting all cancer antigens at once, it eliminates the need to identify specific antigens and mounts a more effective immune response. This encourages pharma startups to expand tumor cell vaccines for the treatment of different cancers.
BioVaxys is a Canadian startup developing viral and oncologic vaccines. The startup’s vaccine platform is based on haptenization, a process that makes target proteins more visible to the immune system. BVX-0918A, the startup’s lead tumor cell vaccine, injects the patient’s own cancer cells, haptenized in vitro, to generate a strong immune response. BioVaxys is also developing a monovalent haptenized vaccine for SARS-CoV-2.
Discover more Pharma Startups
Pharma startups such as the examples highlighted in this report focus on artificial intelligence, blockchain, precision medicine as well as digital therapeutics. While all of these technologies play a major role in advancing the pharma industry, they only represent the tip of the iceberg. To explore more pharma technologies, simply get in touch to let us look into your areas of interest. For a more general overview, you can download our free Pharma Innovation Report to save your time and improve strategic decision-making.
